ChemDiv, a California-based global provider of integrated drug discovery solutions, announced on Friday that it is continuing to provide chemistry, computational and clinical pharmacology support to Clywedog Therapeutics.
The company is taking this step as it enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The merged company will operate under the name Clywedog Therapeutics Inc and is expected to be listed on Nasdaq under the ticker CLYD upon closing.
The merged portfolio will concentrate on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.
ChemDiv's ongoing partnerships includes accelerated CMC research, AI-enabled pharmacology, computational modelling and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023-2024.
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
ZYUS Life Sciences receives second US pain management patent
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cirius Therapeutics introduces gestational diabetes initiative
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
AOTI reports strong real-world outcomes for TWO2 wound therapy
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
EKF Diagnostics acquires Beep Insights technology to expand sports performance offering
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval